ライフサイエンスコーパス: pharmacodynamic

1 in part B (to assess safety and longer-term pharmacodynamics).

2 gnitude and duration of response to therapy (pharmacodynamics).

3 exosomes to intercellular drug transfer and pharmacodynamics.

4 eir assembly, stability, immunogenicity, and pharmacodynamics.

5 acokinetic profile for assessment of in vivo pharmacodynamics.

6 c disturbance per se is unrelated to altered pharmacodynamics.

7 se is related to altered pharmacokinetics or pharmacodynamics.

8 acology of AMG 416 showed readily reversible pharmacodynamics.

9 unds impacting on their pharmacokinetics and pharmacodynamics.

10 ed pharmacokinetics, antitumor activity, and pharmacodynamics.

11 orbidities, and altered pharmacokinetics and pharmacodynamics.

12 for understanding their pharmacokinetics and pharmacodynamics.

13 y and optimizing antibiotic pharmacokinetics/pharmacodynamics.

14 n be exploited to comprehensively understand pharmacodynamic actions, although proper frameworks to r

15 en the dose-limiting CRS at higher doses and pharmacodynamic activity at lower doses.

16 e, compound 39 (AM-0466) demonstrated robust pharmacodynamic activity in a NaV1.7-dependent model of

17 tionships between in vivo target engagement, pharmacodynamic activity, and efficacy in chronic diseas

18 ptable pharmacokinetic properties and robust pharmacodynamic activity.

19 Additional pharmacokinetic and pharmacodynamic analyses in these mice explain why clini

20 ch and by more sophisticated pharmacokinetic/pharmacodynamic analyses of drug action; the two approac

21 Pharmacokinetic and pharmacodynamic analyses support the concentration-depen

22 Pharmacokinetic and pharmacodynamic analyses to determine the biologically e

23 Pharmacodynamic analysis of BRAF V600E downstream target

24 ood, Sehgal et al report on the clinical and pharmacodynamics analysis of pomalidomide dosing strateg

25 These human pharmacodynamic and pharmacokinetic data, although limit

26 ied selective KOP-r antagonists have unusual pharmacodynamic and pharmacokinetic properties (slow dev

27 um or tissue eosinophil counts, evolved as a pharmacodynamic and predictive biomarker for the efficac

28 However, pharmacodynamic and safety studies are necessary to furt

29 murine model that can be used to analyze the pharmacodynamics and antitumor properties of immunostimu

30 evaluates the safety, pharmacokinetics, and pharmacodynamics and defines the recommended phase II do

31 traightforward to relate pharmacokinetics to pharmacodynamics and efficacy by following the time abov

32 riteria for Adverse Events version 4.03, and pharmacodynamics and immunogenicity were also evaluated.

33 n, FQ plasma and tissue pharmacokinetics and pharmacodynamics and is based on extensive in vitro and

34 Assessment of safety, pharmacodynamics and nasal allergic reactivity following

35 ns, and fail to fully capture cytotoxic drug pharmacodynamics and pharmacokinetic variability in obes

36 We explored the pharmacodynamics and pharmacokinetics in a rabbit model.

37 However, improvement of the drug's pharmacodynamics and pharmacokinetics is desirable.

38 al drawbacks with such peptides include poor pharmacodynamics and potential scrambling of the disulfi

39 ion cohort; on the basis of pharmacokinetic, pharmacodynamic, and safety information, we chose a dose

40 and the schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of oral BGJ398,

41 tives were to evaluate the pharmacokinetics, pharmacodynamics, and clinical antitumor activity of var

42 rial, we evaluated the safety, tolerability, pharmacodynamics, and efficacy of lumacaftor/ivacaftor c

43 rial evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of selinexor (KPT-330), a

44 o characterize the safety, pharmacokinetics, pharmacodynamics, and efficacy, and to identify the reco

45 cidence of adverse events, pharmacokinetics, pharmacodynamics, and overall response rate.

46 dy to evaluate the safety, pharmacokinetics, pharmacodynamics, and potency of i.v. administrations in

47 were safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity.

48 ing drug pharmacokinetics, measuring therapy pharmacodynamics, and providing a marker of therapeutic

49 We determined the safety, pharmacokinetics, pharmacodynamics, and recommended phase II dose of MK-87

50 ly images bone metabolism and may serve as a pharmacodynamic assessment for systemic therapy such as

51 Pharmacodynamic assessment of the systemic effect of inh

52 Pharmacodynamic assessments measured by vasodilator-stim

53 Pharmacodynamic assessments were conducted using 4 diffe

54 acokinetics (ABCG2, AHR, POR and CYP1A2) and pharmacodynamics (BDNF and SLC6A4) of caffeine.

55 inical responses were observed, demonstrated pharmacodynamic biomarker activity, and had a manageable

56 tly, our findings posit that 40 Hz ASSR is a pharmacodynamic biomarker for cortical NMDA function tha

57 demonstrated modulation of phospho-STAT1, a pharmacodynamic biomarker of CDK8 activity, and tumor gr

58 SPP1 rs28357094 acts as a pharmacodynamic biomarker of GC response, and LTBP4 hapl

59 2, respectively), and a 2-gene, longitudinal pharmacodynamic biomarker of SSc skin disease decreased

60 eventy-two studies included a biopsy-derived pharmacodynamic biomarker.

61 Hsp70 drug discovery by providing XIAP as a pharmacodynamic biomarker.

62 d that could be combined into a longitudinal pharmacodynamic biomarker.

63 employ conservative designs that incorporate pharmacodynamics/biomarker monitoring.

64 studies including the use of biopsy-derived pharmacodynamic biomarkers between 2003 and 2010.

65 cidated, and no validated pharmacokinetic or pharmacodynamic biomarkers exist.

66 It also provides potential pharmacodynamic biomarkers for anti-mitotic cancer chemo

67 A panel of new pharmacodynamic biomarkers for corticosteroids in childr

68 increased use, the impact of biopsy-derived pharmacodynamic biomarkers in phase I oncology studies o

69 The use of biopsy-derived pharmacodynamic biomarkers is increasing in early-phase

70 We examined the impact of biopsy-derived pharmacodynamic biomarkers on subsequent drug developmen

71 p develop combination strategies or identify pharmacodynamic biomarkers to support the clinical devel

72 nced by the effect on interleukin-13-related pharmacodynamic biomarkers, and clinically relevant chan

73 studies identified potential predictive and pharmacodynamic biomarkers.

74 argeting antibody pembrolizumab and identify pharmacodynamic changes in circulating exhausted-phenoty

75 fore and during treatment were evaluated for pharmacodynamic changes.

76 tives were to assess the pharmacokinetic and pharmacodynamic characteristics and safety of fitusiran.

77 hydroartemisinin and has pharmacokinetic and pharmacodynamic characteristics compatible with a single

78 nformation regarding the pharmacokinetic and pharmacodynamic characteristics of 1, it was demonstrate

79 The pharmacodynamic characteristics of CPP-115 remain to be

80 SED) delivery system in dogs and to evaluate pharmacodynamic characteristics of SED against H1650 ste

81 2 mg daily), 17 of whom were enrolled onto a pharmacodynamic cohort undergoing mandatory biopsies bef

82 lamanid, and linezolid), pharmacokinetic and pharmacodynamic considerations, preventive strategies (s

83 iable biochemical read out of steroidal drug pharmacodynamics could enable a rapid and objective asse

84 marizes the discovery, pharmacokinetics, and pharmacodynamic data in preclinical species and human su

85 In vivo pharmacodynamic data in rabbit model showed sustained re

86 y, toxicology, and mouse pharmacokinetic and pharmacodynamic data provided a solid basis for establis

87 The pharmacokinetics/pharmacodynamics data were used to identify model parame

88 bine, these compounds demonstrate an in vivo pharmacodynamic effect and are efficacious in a mouse p5

89 th AMG 416 in pigs showed a complete lack of pharmacodynamic effect and provided a foundation for det

90 n dosed in ZDF rats, 25 showed both a robust pharmacodynamic effect as well as a statistically signif

91 strates that tralokinumab prevents the IL-13 pharmacodynamic effect by binding to IL-13 helices A and

92 6n-2 exhibits a robust acute pharmacodynamic effect in cynomolgus monkeys (ED50 0.12

93 eripheral insulin changes, conclude that the pharmacodynamic effect is centrally driven.

94 terogeneity in EGFR activity, as well as the pharmacodynamic effect of a radionuclide-labeled EGFR in

95 tions in serum phosphate, a manifestation of pharmacodynamic effect, occurred in all patients startin

96 o-controlled, crossover trial evaluating the pharmacodynamic effects of a single oral dose of NDI-010

97 Here we evaluated the clinical and pharmacodynamic effects of continuous or intermittent do

98 troscopy studies that characterize the acute pharmacodynamic effects of CPP-115 with additional dose-

99 ilability in preclinical species and exhibit pharmacodynamic effects of S1P1 antagonism in several in

100 dingly, in this review, we summarize the key pharmacodynamic effects of SGLT2 inhibitors and the clin

101 Improved understanding of pharmacodynamic effects of these agents in patients will

102 ells, and in vivo assays demonstrate durable pharmacodynamic effects on ITK, which reduces an oxazolo

103 complete suppression of IgE provided greater pharmacodynamic effects, including suppression of skin p

104 In vivo pharmacodynamic efficacy was evaluated using Morris Wate

105 e curves of beta-lap in tumors, and enhanced pharmacodynamic endpoints (e.g., PARP1 hyperactivation,

106 The ability of the model to forecast pharmacodynamic endpoints was validated retrospectively

107 In vitro and in vivo pharmacokinetic and pharmacodynamic evaluation allowed the selection of comp

108 (Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coat

109 ided a good relationship for pharmacokinetic/pharmacodynamic evaluations.

110 KMO in vivo with this lead compound provides pharmacodynamic evidence for modulation of kynurenine pa

111 Despite pharmacodynamic evidence for robust on-target activity,

112 doperoxide with combined pharmacokinetic and pharmacodynamic features that overcome the liabilities o

113 e display stereospecific pharmacokinetic and pharmacodynamic features.

114 inhibitor with improved pharmacokinetic and pharmacodynamic features.

115 ors sought to study the pharmacokinetics and pharmacodynamics for ticagrelor 60 mg compared with 90 m

116 Indications of CPT pharmacodynamics from tumor biomarkers such as carbonic

117 tor antagonists, are associated with greater pharmacodynamic inhibition and reduction of cardiovascul

118 d uptake of siRNA into the cell and improved pharmacodynamics inside the cell.

119 PfMDR1 could also significantly modulate the pharmacodynamic interactions of the compounds and that t

120 entified active chemical species and resolve pharmacodynamic interactions within other chemically com

121 ity of resistance emergence at the molecular pharmacodynamic level and might even reverse tumor resis

122 a level expected to support modulation of a pharmacodynamic marker in mouse was achieved when the co

123 rts is the lack of a suitable, non-invasive, pharmacodynamic marker of EWS-FLI1 activity.

124 erythropoietin, a HIF-2 target and possible pharmacodynamic marker.

125 stained increase in plasma PlGF, a potential pharmacodynamic marker.

126 t of neuroimmunological diseases and provide pharmacodynamic markers for future therapeutic developme

127 tion of MLL-r tumor growth and inhibition of pharmacodynamic markers of DOT1L activity.

128 n this study, we developed a pharmacokinetic/pharmacodynamic mathematical model that identifies in si

129 suggest that knemometry is a more sensitive pharmacodynamic measure of systemic effects of ICSs than

130 Safety, the side-effect profile, and pharmacodynamic measures (PCSK9 level, LDL cholesterol l

131 ty, side-effect profile, pharmacokinetic and pharmacodynamic measures, and changes in levels of lipid

132 SK2141795 pharmacokinetics and (18)F-FDG PET pharmacodynamic measures; however, an exposure-response

133 In a rat LPS-induced TNFalpha pharmacodynamic model and a rat adjuvant arthritis model

134 reby establishing an in vivo pharmacokinetic/pharmacodynamic model for CP-456,773.

135 ectivity over S1P3 and were efficacious in a pharmacodynamic model of suppression of circulating lymp

136 A discrete-time pharmacodynamic model of the combination of radiotherapy

137 The pharmacodynamic model of the PACAP-PAC1 interaction best

138 ach to establish an in vitro pharmacokinetic/pharmacodynamic model to describe how the concentration

139 e applied a semi-mechanistic pharmacokinetic/pharmacodynamic model to enable prediction of in vivo ef

140 which was advanced into a target engagement pharmacodynamic model where it exhibited robust reversal

141 iated c-Met phosphorylation in a mouse liver pharmacodynamic model.

142 esian network modeling and a pharmacokinetic-pharmacodynamic model.

143 The computational pharmacokinetics/pharmacodynamics model can be generalized to predict who

144 gically based computational pharmacokinetics/pharmacodynamics model was constructed to simulate the r

145 y shown that mechanism-based pharmacokinetic/pharmacodynamic modeling enables integration of nonvalid

146 Using pharmacokinetic-pharmacodynamic modelling and mouse-human bridging analy

147 suggested recently, based on pharmacokinetic-pharmacodynamic modelling exercises, that twice daily do

148 5 showed robust effects in rabbit and canine pharmacodynamic models and an acceptable cross-species p

149 ogram where quantitative pharmacokinetic and pharmacodynamic models more predictive of curative treat

150 ound 45 demonstrated robust efficacy in both pharmacodynamic models with ED90 values <3 mg/kg.

151 Compound 13 showed profound pharmacodynamic modulation of p-Akt in PTEN-deficient PC

152 g according to exposure levels, coupled with pharmacodynamic monitoring based on phosphorylation of S

153 Pharmacodynamic monitoring of belatacept was performed b

154 dualized dosing based on pharmacokinetic and pharmacodynamic monitoring.

155 Here, we used a novel pharmacodynamic neuroimaging approach to identify the ch

156 This study aims to describe the pharmacodynamics of a fluid challenge over a 10-minute p

157 the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib.

158 on should center on the pharmacokinetics and pharmacodynamics of agents in an attempt to ameliorate p

159 nificant impacts on the pharmacokinetics and pharmacodynamics of artemether-lumefantrine treatment.

160 safety, tolerability, pharmacokinetics, and pharmacodynamics of avoralstat.

161 -tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of carfilzomib administered as a 30-min

162 he purpose of this study was to document the pharmacodynamics of CO2 for MBF using prospective end-ti

163 safety, tolerability, pharmacokinetics, and pharmacodynamics of CSL112 in patients with a recent acu

164 The pharmacodynamics of Cyto-012 and wt BoNT/A have similar

165 is of the antiviral effects, toxicities, and pharmacodynamics of different variants of cardiac glycos

166 clearance, alters both pharmacokinetics and pharmacodynamics of furosemide in acute kidney injury, a

167 safety, tolerability, pharmacokinetics, and pharmacodynamics of GP2013 plus cyclophosphamide, vincri

168 e assessed the safety, pharmacokinetics, and pharmacodynamics of ISIS-APO(a)Rx, a second-generation a

169 to assess the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in children aged 2-5 years

170 The pharmacokinetics and pharmacodynamics of lumefantrine, a component of the mos

171 ercellular drug transfer that contributes to pharmacodynamics of neighboring cells.

172 roteins involved in the pharmacokinetics and pharmacodynamics of rasagiline, and genes previously ass

173 safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human LCAT (ACP-501).

174 ndary outcomes were the pharmacokinetics and pharmacodynamics of ricolinostat in this combination and

175 acterize the toxicity, pharmacokinetics, and pharmacodynamics of selinexor, a selective inhibitor of

176 taken by analysing the pharmacokinetics and pharmacodynamics of single doses of subcutaneous aldesle

177 d to reflect pharmacological action and thus pharmacodynamics of the delivered enzyme.

178 nteractions and altered pharmacokinetics and pharmacodynamics of the different antihypertensive medic

179 pairs motor performance concomitant with the pharmacodynamics of the drug, but also impairs future mo

180 We assessed the safety and pharmacodynamics of the vaccine in patients with coeliac

181 emporal tissue pharmacokinetics and in vitro pharmacodynamics of these FQs.

182 The pharmacokinetics and pharmacodynamics of ticagrelor 60 mg bid have not been s

183 mulations and to characterize the safety and pharmacodynamics of triamcinolone acetonide (TA) deliver

184 01 sensitivity offering potential utility as pharmacodynamic or predictive response markers.

185 ficacy was reported, only pharmacokinetic or pharmacodynamic outcomes were reported, or if ten or few

186 Pharmacodynamics outcomes were modeled using a Bayesian

187 Prospective trials that directly compare pharmacodynamic parameters and clinical events among spe

188 Pharmacokinetic, pharmacodynamic parameters, and outcome measures were co

189 e used to assess furosemide pharmacokinetics/pharmacodynamics parameters.

190 ile, these analogs were selected for in vivo pharmacodynamic (PD) and efficacy experiments in animal

191 ine pool size, whose change might reveal the pharmacodynamic (PD) effect of drugs targeting this canc

192 entration, bacterial susceptibility, and the pharmacodynamic (PD) inhibitory effect on the bacterial

193 s, and in vitro dose-response data into a PK/pharmacodynamic (PD) model to allow for placement of che

194 A PK/pharmacodynamic (PD) model was developed by measuring mu

195 10 had the desired pharmacokinetic (PK) and pharmacodynamic (PD) profile and demonstrated maximal ef

196 t uptake potential, pharmacokinetic (PK) and pharmacodynamic (PD) profiles.

197 an investigation of the pharmacokinetic (PK)-pharmacodynamic (PD) relationship based on ex vivo leuko

198 Other objectives were to characterize the PK/pharmacodynamic (PD) relationship, correlate biomarkers

199 Pharmacodynamic (PD) studies comparing ticagrelor versus

200 This is the first systematic pharmacodynamic (PD) study of eculizumab in PNH patients

201 ET and assess the pharmacokinetics (PK) and pharmacodynamics (PD) profile of OA.

202 An understanding of pharmacokinetics (PK), pharmacodynamics (PD), antimicrobial susceptibility test

203 imum tolerated dose (MTD), pharmacokinetics, pharmacodynamics (PD), efficacy, and safety of duvelisib

204 ion affecting drug pharmacokinetics (PK) and pharmacodynamics (PD).

205 rmacokinetics [PK]) and protective efficacy (pharmacodynamics [PD]).

206 KG-1a xenograft tumors in vivo with a clear pharmacodynamic-pharmacokinetic relationship.

207 tment and follow-up and were included in the pharmacodynamics, pharmacokinetics, and safety analyses.

208 the three major pillars of drug development-pharmacodynamics, pharmacokinetics, and toxicity studies

209 We assessed the pharmacodynamics, pharmacokinetics, preliminary efficacy

210 We discuss the pharmacodynamics, pharmacokinetics, toxic effects, and c

211 Through use of this pharmacokinetic-pharmacodynamic (PK-PD) approach we demonstrate that the

212 Semi-mechanistic pharmacokinetic-pharmacodynamic (PK-PD) modeling is increasingly used fo

213 cellular potency and in vivo pharmacokinetic-pharmacodynamic (PK-PD) properties gave a compound with

214 Pharmacokinetic/pharmacodynamic (PK/PD) analysis in patients with isavuc

215 Pharmacokinetic/pharmacodynamic (PK/PD) modeling was applied using effic

216 integrating within-host pharmacokinetic and pharmacodynamic (PK/PD) models with mathematical models

217 e therefore assessed whether pharmacokinetic/pharmacodynamic (PK/PD) parameters could predict 2-month

218 Antimicrobial pharmacokinetic-pharmacodynamic (PK/PD) science is vital to early antibi

219 Here we use pharmacokinetics/pharmacodynamics (PK/PD) analysis to rationally develop

220 -TB) is designed to perform pharmacokinetics/pharmacodynamics (PK/PD) experiments, and hence the desi

221 arge number of tuberculosis pharmacokinetics/pharmacodynamics (PK/PD) studies that have not been subj

222 on was driven by a modified pharmacokinetics-pharmacodynamics (PK/PD)-based dosing approach.

223 file are provided as well as pharmacokinetic-pharmacodynamic (PKPD) correlations to analyze the trend

224 -effective-concentration (MEC, 25 ng/mL) and pharmacodynamic (plasma HIV RNA) parameters were assesse

225 idered, including viral pharmacokinetics and pharmacodynamics, potential toxic effects, and monitorin

226 ntrolled crossover study assessed the opioid pharmacodynamic profile following escalating doses of SA

227 The pharmacodynamic profile of lanadelumab was assessed by m

228 fety, acceptability, and pharmacokinetic and pharmacodynamic profile of long-acting rilpivirine.

229 n interval (25-78 min) and consistent with a pharmacodynamic profile showing a peak response at 39-51

230 cin challenge studies; despite this improved pharmacodynamic profile, spontaneous cough frequency did

231 ological and biochemical assays, and in vivo pharmacodynamic profile.

232 rse Events version 4.0), pharmacokinetic and pharmacodynamic profiles (immunological effects), best o

233 on phase on the basis of pharmacokinetic and pharmacodynamic profiles and demonstrated efficacy.

234 more favorable pharmacokinetic and antitumor pharmacodynamic profiles in vivo than that of native TRA

235 ings may be attributed to differences in the pharmacodynamic profiles of these drugs in DM patients r

236 um tolerated dose (MTD), pharmacokinetic and pharmacodynamic profiles, safety, and clinical activity

237 On the basis of safety, pharmacokinetic, and pharmacodynamic profiling, the RP2D was defined as 800 m

238 h significantly improved pharmacokinetic and pharmacodynamic properties as compared to 2.

239 e(II) reactivity and the pharmacokinetic and pharmacodynamic properties of 1,2,4-trioxolane antimalar

240 ugh understanding of the pharmacokinetic and pharmacodynamic properties of a drug in animal models is

241 Pharmacodynamic properties of both compounds are discuss

242 Here we examined the pharmacodynamic properties of chronic morphine in mice f

243 tal tool to evaluate the pharmacokinetic and pharmacodynamic properties of selected phytocannabinoids

244 has highlighted unusual pharmacokinetic and pharmacodynamic properties of these compounds, including

245 ections, then (i) antibiotics with different pharmacodynamic properties would be similarly effective,

246 de, medicinal chemistry, pharmacokinetic and pharmacodynamic properties, and in vivo pharmacology/tox

247 by chance an anti-CD20 mAb with equilibrated pharmacodynamic properties, the reinforcement of some of

248 been an effective strategy for tuning their pharmacodynamic properties, with more than 40 new drugs

249 o the parasite, and AL's pharmacokinetic and pharmacodynamic properties.

250 ate a functional ADRA1D isoform with optimal pharmacodynamic properties.

251 n order to improve their pharmacokinetic and pharmacodynamic properties.

252 sign of covalent inhibitors with appropriate pharmacodynamics properties coupled with limited unwante

253 ay, in part, be parkin-independent or to the pharmacodynamics properties of nilotinib.

254 tically characterize the pharmacokinetic and pharmacodynamics properties of the SMN splicing modifier

255 that might be exploited for therapeutic and pharmacodynamic purposes.

256 lyglutamine-expanded proteins as well as the pharmacodynamics readouts to monitor their efficacy in p

257 rocessing events and defines pharmacokinetic-pharmacodynamic relationships.

258 Finally, to test the pharmacodynamic relevance of the proposed biomarker, two

259 ain after systemic dosing, and a significant pharmacodynamic response as measured by brain Abeta redu

260 ictive assay and method of assessing in vivo pharmacodynamic response to endocrine therapy.

261 iloring therapy based on pharmacokinetics or pharmacodynamic response, as well.

262 tered pharmacokinetics (p < 0.01), a reduced pharmacodynamics response to furosemide also became impo

263 protocol could differentiate phenotypic and pharmacodynamic responses to Selumetinib (0-3uM).

264 We evaluated the pharmacokinetics (PKs), pharmacodynamics, safety, and efficacy of selinexor, an

265 l evaluation of ETX0914 pharmacokinetics and pharmacodynamics showed distribution into vascular tissu

266 In vivo pharmacodynamic studies demonstrated significantly highe

267 Subsequent pharmacokinetic and pharmacodynamic studies identified BMS-814580 (compound

268 Pharmacokinetic and pharmacodynamic studies in guinea pigs showed that a sin

269 esent method will enable pharmacokinetic and pharmacodynamic studies of p-XSC in both clinical and pr

270 Pharmacodynamic studies showed preliminary evidence of A

271 Our pharmacodynamic studies showed that at clinically releva

272 Pharmacodynamic studies showed that minocycline depletes

273 Pharmacokinetic and pharmacodynamic studies were performed on days 1 and 22.

274 been further profiled in in vivo safety and pharmacodynamic studies.

275 Human pharmacokinetics/pharmacodynamics studies confirmed this link between mic

276 tigation of kinetic mechanisms in disease or pharmacodynamics studies using MS data from longitudinal

277 cokinetic analyses, in vivo pharmacokinetics/pharmacodynamics studies, and maximum-tolerated-dose stu

278 cted an intensive and sparse pharmacokinetic/pharmacodynamic study in Uganda of the most widely adopt

279 mized, double-blind, double-dummy, crossover pharmacodynamic study, aspirin-treated DM patients (n=50

280 ive pathogens include (1) a pharmacokinetics/pharmacodynamics study to evaluate the impact of vancomy

281 8 patients enrolled in a pharmacokinetic and pharmacodynamic substudy from 4 phase 2 trials, circulat

282 rated cellular PTX pharmacokinetics with PTX pharmacodynamics successfully predicted effects of exoso

283 reakpoint change improves the probability of pharmacodynamic target attainment and eliminates the nee

284 ble for once a day oral dosing, achieved its pharmacodynamic target for PARP inhibition, and had prom

285 evertheless, clear cerebrospinal fluid (CSF) pharmacodynamic targets are not known.

286 ovided preferred irreversible inhibitors for pharmacodynamic testing in vivo.

287 physical function, frailty, disability, and pharmacodynamics that all merit further investigation.

288 of fMRI affords detailed mapping of regional pharmacodynamics that underlie mechanisms of pain suppre

289 PR1 and VIPR2 to improve pharmacokinetic and pharmacodynamic therapeutic end points.

290 orating viral dynamics and pharmacokinetics/ pharmacodynamics to assess how suboptimal adherence affe

291 ing of intratumoral TNP pharmacokinetics and pharmacodynamics to better comprehend their heterogeneou

292 h vein injection, and exhibited the expected pharmacodynamics to remove uric acid in hyperuricemic bl

293 This study evaluated the pharmacokinetics, pharmacodynamics, tolerability, safety, and efficacy of

294 -miR, which is more robust than conventional pharmacodynamics using downstream target gene derepressi

295 formulation is a major factor in optimizing pharmacodynamics using this technique.

296 a combination of MIC values, pharmacokinetic/pharmacodynamic values, and clinical outcome data.

297 ures and pharmacokinetics were assessed, and pharmacodynamics were measured in blood, hair follicles,

298 Efficacy and pharmacodynamics were secondary end points.

299 nt altered indomethacin pharmacokinetics and pharmacodynamics, which is probably the result of reduce

300 the RTB carrier may support distinct in vivo pharmacodynamics with potential to address hard-to-treat